This conference brings together researchers from both academia and industry, and will discuss the development of techniques and tools implemented in High Content technologies and Phenotypic Screening applications.
Axol Biosciences Ltd, the Cambridge-based biotechnology company specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems for the drug discovery industry, recently announced the appointment of Dr. Paul Andrews, NPSC's Director of Operations to their Scientific Advisory Board (SAB). Paul's appointment follows on from NPSC's ongoing collaborations to use Axol's neural progenitor cells for drug discovery. The other members of the SAB are Chris Torrance (Horizon Discovery), Steve Rees (AstraZeneca), Chas Bountra (SGC/University of Oxford) and Darren Disly (Horizon Discovery Group)
The technology for viewing, sharing, analysis and management of large sets of images and metadata will enable new collaborations and research.
Glencoe Software, the world-leading supplier of image data management solutions for biotech, pharma and publication industries, will provide the data management solution OMERO Plus for the newly established National Phenotypic Screening Centre (NPSC). Phenotypic analysis measures the characteristics and behavior of cells, tissues and even whole organisms, allowing comparisons between states such as health and disease, the presence or absence of toxins or drugs, or the effect of genetic mutants. A key challenge for NPSC is the development of automated workflows or “smart assays” that combine robotics with the use of advanced informatics and decision analytics in real-time to screen large numbers of potential drugs as efficiently and effectively as possible. NPSC is a highly collaborative environment with multiple partners worldwide requiring data sharing to be seamless and secure. To deliver on these requirements, NPSC has chosen Glencoe Software’s OMERO Plus data management, storage and integration technology to meet this challenge.
The Universities of Dundee, Oxford and Edinburgh have announced the formation of the Phenomics Discovery Initiative (PDi) with Janssen Pharmaceutica N.V. the first industry partner joining the initiative.
A phenotype is one or more observable features or traits that report changes in a biological system or its reaction its environment. Phenotypic screening is the systematic identification of agents (such as small molecules, biological molecules or genetic mutations) that alter a phenotype.
Phenotypic changes are a factor in most diseases, whether it is a cancer cell undergoing uncontrolled cell division, a motor neuron that fails to connect to muscle tissue, or the complex defects seen in the brain of a patient with schizophrenia.